Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is transitioning due to changes in Medicare reimbursement and facing slower market recovery due to pricing and payment process confusion. The success of their products is dependent on tissue donorship, procurement scalability, and competition in the evolving skin substitute landscape. Revenue risk is present as 76% of 2024 revenue is from membership in primary GPOs or IDNs; a 20% base salary reduction from the CEO and heightened cost control measures highlight MDXG's commitment to growth initiatives despite this, and management will elaborate on how such initiatives and restructuring intend to drive higher growth in their Q2'26 conference call.

Bears say

MiMedx Group is currently facing multiple challenges that are negatively impacting its financial performance and outlook. These include the negative impact of recent CMS reimbursement changes, a decline in sales due to disruptions caused by the COVID-19 pandemic, and a reduction in workforce to cut costs. While the company has a strong portfolio of products and a vertically integrated manufacturing infrastructure, it may still take some time for demand to return to normal levels. Additionally, the company's recent restructuring efforts are expected to result in annual savings of $40 million, but this may not be enough to offset the current challenges it is facing.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.